Merck & Co., Inc. $MRK Shares Bought by Caprock Group LLC

Key Points

• Caprock Group LLC boosted its stake in Merck by 22.1% in Q4, buying 14,031 shares to hold 77,418 shares worth about $8.21 million.
• Merck struck a multi‑year partnership with Google Cloud (valued up to $1 billion) and scored regulatory wins — FDA approval of IDVYNSO and EU approval for ENFLONSIA — supporting near‑term commercial upside.
• Offsetting those positives, a Phase 3 LITESPARK‑012 combination trial in first‑line advanced renal cell carcinoma failed to meet primary endpoints, spurring investor concern and recent share weakness.

Caprock Group LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 22.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 77,418 shares of the company's stock after buying an additional 14,031 shares during the period. Caprock Group LLC's holdings in Merck & Co., Inc. were worth $8,212,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. DLD Asset Management LP lifted its stake in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Merck & Co., Inc. by 5.9% in the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock valued at $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of Merck & Co., Inc. by 2.0% in the 3rd quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company's stock valued at $876,600,000 after purchasing an additional 209,759 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Announced a multi‑year partnership with Google Cloud valued at up to $1 billion to deploy agentic AI across R&D, manufacturing and commercial functions — a potential productivity and R&D acceleration catalyst that could improve long‑term margins and pipeline efficiency. Merck to partner with Google Cloud on AI initiatives
• Positive Sentiment: FDA approved Merck’s once‑daily IDVYNSO (doravirine/islatravir) for HIV-1 — a new oral two‑drug regimen that expands Merck’s infectious‑disease franchise and provides near‑term commercial upside. FDA Approves Merck's Once-Daily IDVYNSO
• Positive Sentiment: Won EU approval for ENFLONSIA to protect infants from RSV — another regulatory win that supports near‑term revenue diversification in vaccines. Merck Wins EU Approval for ENFLONSIA
• Neutral Sentiment: Reported interest in Inhibrx’s Keytruda‑linked experimental cancer drug from multiple buyers including Merck — potential M&A optionality but uncertain timing/value. Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug
• Neutral Sentiment: Market report flags increasing competition in polycythemia vera with several entrants (including Merck’s bomedemstat) in development — underscores both addressable market growth and increasing competitive risk over the next decade. Polycythemia Vera Market Set for Transformation
• Negative Sentiment: Merck and Eisai said the Phase 3 LITESPARK‑012 combination in first‑line advanced renal cell carcinoma failed to meet primary endpoints — a notable clinical setback that reduced near‑term oncology upside and pushed shares lower in recent sessions. Merck‑Eisai's combination cancer therapy fails meet main goals
• Negative Sentiment: Market coverage highlights the stock decline after the kidney‑cancer trial miss, reflecting investor concern over Keytruda‑combination setbacks even as Keytruda remains a major revenue driver. MRK Down as Triplet Therapy Fails to Meet Goal

Merck & Co., Inc. Price Performance

MRK stock opened at $112.87 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $278.77 billion, a PE ratio of 15.50, a P/E/G ratio of 2.26 and a beta of 0.26. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The business's fifty day moving average price is $118.89 and its 200 day moving average price is $106.53.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 4.93 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s payout ratio is currently 46.70%.

Insider Transactions at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 10,000 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares in the company, valued at $2,583,278.39. This represents a 41.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on MRK shares. Zacks Research raised Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. TD Cowen upped their price target on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research note on Tuesday, January 20th. Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target on the stock. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $128.47.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.